FDA Adult Antidepressant Suicidality Analysis Will Take At Least A Year
Executive Summary
FDA expects its assessment of data on suicidal thinking and behavior in adults on antidepressants will take at least a year to complete
You may also be interested in...
FDA Stance On Antidepressant Warnings Unchanged By NIMH Suicide Findings
A National Institute of Mental Health-funded study showing no increased risk of suicide with newer antidepressants does not change FDA's stance on the need for warnings about suicidality for the drug class
FDA Stance On Antidepressant Warnings Unchanged By NIMH Suicide Findings
A National Institute of Mental Health-funded study showing no increased risk of suicide with newer antidepressants does not change FDA's stance on the need for warnings about suicidality for the drug class
J&J To Promote Dapoxetine With “Responsible” DTC Campaign
Johnson & Johnson plans to support the launch of the premature ejaculation therapy dapoxetine with a "responsible" direct-to-consumer advertising campaign, J&J Consumer Pharmaceuticals & Nutritionals Group Chairman Rosemary Crane said May 26 during the company's R&D day in New York